Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer

NCT05838729 is registered in ClinicalTrials.gov with Coordination Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05838729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05838729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer
Lead sponsor
Coordination Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 3, 2023
Completion date
December 31, 2026
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head neck cancer, intratumoral injection